Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

NCT07587021 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria Type 1
PH1

Interventions

GENETIC: YOLT-203
DRUG: Placebo

Sponsor

YolTech Therapeutics Co., Ltd